Coker RJ, Viviani M, Gazzard BG, Du Pont B, Pohle HD, Murphy SM, Atouguia J, Champalimaud JL, Harris JR. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS.
AIDS 1993;
7:829-35. [PMID:
8363759 DOI:
10.1097/00002030-199306000-00011]
[Citation(s) in RCA: 89] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
OBJECTIVE
To determine the safety and efficacy of liposomal amphotericin B (AmBisome) in the primary treatment of AIDS-associated cryptococcosis.
DESIGN
A Phase II, multicentre, European, non-comparative, open study to assess the use of AmBisome in 23 patients (26 enrolments) with cryptococcosis. Dose requirements, mycological response and toxicity were documented.
SETTING
Hospital-based HIV units.
PATIENTS
Twenty-three HIV-1-seropositive patients.
RESULTS
Drug toxicity, assessed in 25 enrolments, was well-tolerated with little renal, hepatic or haematological toxicity. Eighteen out of 23 (78%) enrolments responded clinically. Nineteen enrolments had cryptococcal meningitis: sterilization of spinal fluid was achieved in 12 out of the 18 (67%) who were mycologically evaluable. Fourteen out of the 19 (74%) responded clinically.
CONCLUSION
AmBisome is well-tolerated and may be an effective formulation in the treatment of cryptococcosis.
Collapse